CDR3
CDR314About
What does CDR3 do?
CDR3 performs multi-layered, high-resolution analysis of the T-cell receptor (TCR) repertoire. This technology enables the discovery of new insights from the immunological repertoire, particularly for therapeutic development and understanding immune responses, offering a deeper understanding of the immune system.
When was CDR3 founded?
CDR3 was founded in 2018.
What industry does CDR3 operate in?
CDR3 operates in Healthcare, Immunology, Genomics, Computational Biology, Biotech, HealthTech.
What is CDR3's current status?
CDR3's current operating status is: Inactive.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
AI-powered platform for personalized health and longevity.
Automated ACMG classification, phenotype matching, and clinical reporting for genetic diagnostics, transforming raw genomic data into actionable clinical insights.
Explore cutting-edge bio technology solutions with AI, launching soon.
AI-powered platform accelerating biological research and drug discovery.
Proprietary nutritional analysis systems for wellbeing, sports, and grocery retail.
Apimedtech is developing a novel platform for personalized medicine, leveraging AI and advanced analytics to improve patient outcomes.
Bioexplorer is a platform that leverages AI to help users explore and understand biological data, including genes, proteins, and diseases.
An entrant is a company tagged Genomics whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.